Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Investor Presentation (July 2022)
24 slides from Novaccess Global's investor presentation, July 2022
Slide 1: NovAccess Global
Confidential and Proprietary. Copyright 2022 by NovAccess Global, Inc. All Rights Reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 3: About Us
About Us About Us IND stage biopharmaceutical company developing next‐generation immunotherapies to treat brain cancer An SEC-registered, OTC Markets public company seeking FDA approval for a phase I or IIa human clinical trial An expert scientific and managerial team focused on bringing novel cance
Slide 4: Our Focused Mission
Our Focused Mission Acquisition of cutting-edge assets in oncology Enhance and accelerate bringing to market novel brain Utilization of our expert tumor immunotherapies advisory board to accelerate going to market Confidential 2022 4
Slide 5: Dr. Dwain Irvin, CEO
Dr. Dwain Irvin, CEO EDUCATIONAL BACKGROUND PhD, UCLA School of Medicine, Molecular & Medical Pharmacology, 2002 MPH, UCLA School of Public Health, Environmental Sciences, 1995 BA, The Johns Hopkins University, 1988 Asst. Professor, Research Scientist, Cedars-Sinai Medical Center, Neurosurgery Depar
Slide 6: Dr. Dwain Irvin, CEO
Dr. Dwain Irvin, CEO VENTURES Co-Founder of 2 start-up companies in Biotechnology and Stem Cell Biology CEO, NovAccess Global Inc. 2020 - present Accelerating and Investing in cancer Therapeutics and Diagnostics President, Biotech Division, Innovest Global Inc. 2018 – 2020 Acquire biotech companies
Slide 7: Our Team
Our Team Each Contributor, an Expert in their Field - Highly Focused, yet Adaptable Management Board of Directors Scientific Advisory Board John Cassarini Portfolio Management Renard Currie MBA Andrew Norris Ph.D. Dwain Irvin Ph.D., MPH Executive, XSNX Board Manages product portfolio for Co-Founder,
Slide 8: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma • More than 21,000 brain tumors diagnoses were estimated for 2021 in the U.S. • Glioblastoma is the most common primary adult brain tumor • Five-year survival rates are less than 5% for Glioblastoma • Despite advances in Radiation and Chemotherapy no change in Glioblas
Slide 9: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma Problem: • Standard of Care: Surgical resection followed by radiation and chemotherapy • 15-month median survival • No Cures, additional Glioblastoma therapies needed Solution: • Immunotherapy: 3 Major Types 1. Administration of antigen-pulsed dendritic cell (DC) immun
Slide 10: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma Market Analysis: • 2018, Global, $700 Million Market size, CAGR 9.3% (GlobalData Inc. 2019) • 2026, US, 2.9 Billion Market Size (GlobalData Inc. 2019) • Unmet need - No current immunotherapy for brain tumors • Expect 5% market penetration within first 5 years in market
Slide 11: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma History of TLR-AD1 Technology • Licensed from Cedars-Sinai Medical Center, Department of Neurosurgery • Cedars-Sinai Medical Center ranked 8th in US; Neurosurgery Department ranked 12th in US (US World New and Reports, 2020) • NovAccess Global technology is 3rd Generat
Slide 12: TLR-AD1 Immunotherapy for Glioblastoma
TLR-AD1 Immunotherapy for Glioblastoma Dendritic Cell Vaccine (1st Generation) • Improves survival in responders (Phase I and II) • Not a cure - Reduces chance of Glioblastoma recurrence • Needs improvement-survival rates, outcomes Confidential 2022 12
Slide 13: TLR-AD1 Immunotherapy for Glioblastoma
TLR-AD1 Immunotherapy for Glioblastoma 3rd Generation Immunotherapy: TLR-AD1 • 3rd Generation ‣ 35% improvement over 1st generation in animals • 1st and 2nd Generation ‣ Improves survival in Glioblastoma responders (Phase I, II) ✴ NOT a cure – Reduces chance of Glioblastoma recurrence Confidential 2
Slide 14: TLR-AD1 Immunotherapy for Glioblastoma
TLR-AD1 Immunotherapy for Glioblastoma Step 1: Neurosurgeon isolates Tumor and Immune Cells - Sends to Lab TUMOR TUMOR ANTIGEN CELLS BLOOD ANTIGEN- PRESENTING CELLS (Dendritic Immune Cells) Confidential 2022 14
Slide 15: TLR-AD1 Immunotherapy for Glioblastoma
TLR-AD1 Immunotherapy for Glioblastoma Step 2: Immune Cells Process Tumor Antigens Utilizing TLR-AD1 Technology TUMOR ANTIGEN CELLS ANTIGEN-PRESENTING CELLS (Dendritic Immune Cells) Confidential 2022 15
Slide 16: TLR-AD1 Immunotherapy for Glioblastoma
TLR-AD1 Immunotherapy for Glioblastoma Step 3: TLR-AD1 Glioblastoma Vaccine Administered Glioma Tumor Cell Lysate Antigen specific or antigens derived from bulk lysate combined with Toll- like receptor (TLR) adjuvants ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream T-Cells Trained to
Slide 17: 1st Generation Vaccine - Bulk Tumor Lysate
1st Generation Vaccine - Bulk Tumor Lysate All Post-Vaccine Recurrent Post-Vaccine Patient Frequency Patient Frequency Vaccine Responders Vaccine Non-Responders # Days Survival # Days Survival TTS (time from surgical resection immediately preceding vaccination to time of death) -Wheeler et al, 2008,
Slide 18: 3rd Generation vs. 1st Generation
3rd Generation vs. 1st Generation Pre-Clinical (Animal Study) Kaplan-Mier Survival Analysis of Vaccinated Glioma Bearing Mice (Controls) Vaccine & TLR Combo % Survival Vaccine Median Survival • 1st Gen: 60 days • 3rd Gen + TLR Combos: 81 days # Days Survival Confidential 2022 18
Slide 19: 3rd Generation Vaccine
3rd Generation Vaccine Antigen-specific or antigens derived f rom bulk lysate combined with Toll-like receptor (TLR) adjuvants Pre-clinical mouse model data show signif icant improvements in survival and dendritic cell activation and function Confidential 2022 19
Slide 20: Company Highlights
Company Highlights Q1 2023 Filing IND application to obtain FDA approval for Phase I or IIa human clinical trial Acquisition of cutting-edge assets in oncology Q3 2022 Filed Orphan Drug application Q3 2022 Applying to uplist on OTC Markets (OTCQB) Q3 2022 Partnered with manufacturing CRO Q2 2022 Fil
Slide 21: Milestones Achieved (Brief)
Milestones Achieved (Brief) Q3 2022 Preparing to Up-List on OTC Markets (OTCQB) Initiated recapitalization of company; expected to be completed with diversification of Q1 2022 shareholder base as XSNX shares are distributed to Innovest shareholders Acquisition of cutting-edge assets in oncology FDA
Slide 22: Investor Highlights
Investor Highlights XSNX today is an Investigational New Drug (IND) stage biopharmaceutical company developing next-generation immunotherapy to treat the most common adult brain tumor, Glioblastoma Strong and growing intellectual property portfolio Immunotherapy positioned as platform technology for
Slide 23: Investor Highlights (Cont.)
Investor Highlights (Cont.) Pre-clinical animal data shows significant improvement in survival in animal models for Glioblastoma Orphan drug application filed in July 2022 Recapitalization, additional funding and strengthening of Board/management in early 2022 set stage for significant progress Conf
Slide 24: Thank You!
Thank You! Confidential and Proprietary. Copyright 2022 by NovAccess Global, Inc. All Rights Reserved. novaccessglobal.com